Recombinant Human IFN-gamma (HEK293-expressed) Protein, CF

Name: Recombinant Human IFN-gamma (HEK293-expressed) Protein, CF
Brand: R&D Systems
SKU: 10067-IF
Price: 354 USD
Availability: InStock

R&D Systems | Catalog # 10067-IF

Submit a review

Citations (9)

Product Documents

Analyzed by SEC-MALS

100% Guarantee

Product Specifications
Scientific Data
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

R&D Systems HEK293-derived Recombinant Human IFN-gamma (HEK293-expressed) Protein (10067-IF)
Quality control testing to verify active proteins with lot specific assays by in-house scientists
All R&D Systems proteins are covered with a 100% guarantee

Source

HEK293

Accession Number

NP_000610.2

Structure / Form

Noncovalent homodimer

Applications

Bioactivity

View all IFN-gamma Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human IFN-gamma protein
Met1-Gln166

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Gln24 inferred from enzymatic pyroglutamate treatment revealing Asp25.

Predicted Molecular Mass

16.8 kDa

SDS-PAGE

19-25 kDa, reducing conditions

Activity

Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129.
The ED₅₀ for this effect is 0.06-0.36 ng/mL.

Scientific Data Images for Recombinant Human IFN-gamma (HEK293-expressed) Protein, CF

Recombinant Human IFN‑ gamma (HEK293-expressed) Protein SEC-MALS.

Recombinant Human IFN-G (Catalog # 10067-IF) has a molecular weight (MW) of 37-41 kDa as analyzed by SEC-MALS, suggesting that this protein is a homodimer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (i.e. Glycosylation).

Recombinant Human IFN-gamma (HEK293-expressed) Protein Bioactivity

Recombinant Human IFN-gamma (Catalog # 10067‑IF) demonstrates anti-viral activity in HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED₅₀ for this effect is 0.06‑0.36 ng/mL

Recombinant Human IFN-gamma (HEK293-expressed) Protein SDS-PAGE

2 μg/lane of Recombinant Human IFN‑ gamma (HEK293-expressed) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 19-25 kDa.

Formulation, Preparation, and Storage

10067-IF

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 250 μg/mL in PBS.
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: IFN-gamma

Interferon-gamma (IFN-gamma), also known as type II or immune interferon, exerts a wide range of immunoregulatory activities and is considered to be the prototype proinflammatory cytokine (1, 2). Mature human IFN-gamma exists as a non-covalently linked homodimer of 20-25 kDa variably glycosylated subunits (3). Glycosylation of IFN-gamma at sites Asn25 and Asn97 is critical for protease resistance (4, 5). The mature protein shares 36% and 35% amino acid (aa) sequence identity with mouse and rat IFN-gamma, respectively. IFN-gamma dimers bind to IFN-gamma RI (alpha subunits) which then interact with IFN-gamma RII (beta subunits) to form the functional receptor complex of two alpha and two beta subunits. Inclusion of IFN-gamma RII increases the binding affinity for ligand and the efficiency of signal transduction (6, 7). IFN-gamma is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells (8). It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, up‑regulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects (8, 9). In addition, IFN-gamma functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation (10, 11). The pleiotropic effects of IFN-gamma contribute to the development of multiple aspects of atherosclerosis (9).